Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

1(14.3%)

Phase 3

1(14.3%)

7Total

Phase 1(5)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00815906Phase 1Completed

Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis

Role: collaborator

NCT00641225Phase 1Completed

Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis

Role: collaborator

NCT00521638Phase 1Terminated

Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma

Role: collaborator

NCT00714116Phase 1Completed

Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus

Role: collaborator

NCT01008852Phase 2Completed

Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

Role: collaborator

NCT00127881Phase 3Terminated

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Role: lead

NCT00479622Phase 1Terminated

Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus

Role: collaborator

All 7 trials loaded